Gene therapy faces complexities in delivering treatments due to persistent safety concerns and daunting immune responses, but Next Generation Gene… read more →
For some genetic diseases, there is not only the need to replace the function of a gene that is lost,… read more →
In this podcast episode, the company’s Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company’s dual-functional vector tech… read more →
During the course of conducting interviews, attending conferences and providing other coverage across the region, Scrip‘s on-the-ground team in APAC often… read more →
Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights… read more →
Data Roundup: May 2024 Features Updates from ASGCT in Rare Neurological, Retinal Diseases, and more.
Last month, May 2024, the CGTLive® team was diligently tracking the latest data readouts and published literature on cell and gene… read more →
For global developers of rare disease drugs, China and its 1.4 billion population may offer relatively large pools of patients… read more →
From glaucoma to Stargardt disease, age-related macular degeneration (AMD) to retinitis pigmentosa, or a corneal transplant to Bietti’s crystalline dystrophy,… read more →
Next Generation Gene Therapeutics (NGGT) Biotechnology’s NGGT001, an investigational adeno-associated virus (AAV) vector-based gene therapy intended to treat Bietti’s crystalline… read more →